Search

Your search keyword '"Weroha, S. John"' showing total 322 results

Search Constraints

Start Over You searched for: Author "Weroha, S. John" Remove constraint Author: "Weroha, S. John"
322 results on '"Weroha, S. John"'

Search Results

1. Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors

4. Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer

6. PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

7. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair

8. A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

13. Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

14. Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

15. Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

16. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis

19. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

20. Senolytics improve physical function and increase lifespan in old age

21. Supplementary Materials, Figure S1-S4, Table S1-S9 from Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

22. Data from Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

23. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma

24. Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer

26. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C

27. Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile

28. Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling

29. Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

30. Data from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

31. Supplementary Figures 1-8 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

32. Supplementary Materials and Methods from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma

34. Supplementary Figures S1, Tables S1-S2 from GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors

36. Supplementary Figure Legend from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

37. Supplementary Tables from Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

38. Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

39. Supplementary Methods and oligonucleotide sequences from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

40. Data from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

41. Supplementary Information from Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion

42. Supplementary Data from The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer

43. Figure S3 from Loss of FOXO1 Cooperates with TMPRSS2–ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion

44. Supplementary Figures S1-6. from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

45. Supplementary Table 2 from Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments

46. Supplementary Figures 1 - 4 from Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

47. Supplementary Table 1 from Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments

48. S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models

49. Data from Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer

50. Supplementary Data from Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer

Catalog

Books, media, physical & digital resources